Organization: Ontario Psychiatric Association
CME Accreditation: Mainpro+ group learning credits and MOC Section 1 learning hours
Format: Virtual Event
This event will be recorded, and the recording will be available to the registrants following the event for 14 days after its distribution to registrants.
Conference Chair:
- Valerie Primeau, MD, FRCPC, OPA Executive, North Bay RAAM Physician Lead
Conference Presenters:
- Mike Franklyn, BSc, HBSc, MSc, MD, CCFP
- Wiplove Lamba, MD, FRCPC, Dip ABAM, ISAM (C)
- Valerie Primeau, MD, FRCPC, OPA Executive, North Bay RAAM Physician Lead
Learning Objectives:
Upon attending the day, attendees will be able to:
- Compare and describe current evidence-based pharmacotherapy options for people who use substances in both the withdrawal and maintenance phase, including opiate agonist treatment and anti-craving medications
- Compare and describe psychotherapy principles and available psychosocial treatments for people who use substances
- Engage in a discussion around various treatment approaches for complex patients presenting with concurrent disorders
- Describe the impact of Adverse Childhood Experiences (ACEs) on the Treatment of Mental Health and Addictions
ACCREDITATION INFORMATION
This program has been certified and accredited for up to 8 Mainpro+ group learning credits and MOC Section 1 learning hours.
This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the Continuing Education and Professional Development Office at the Northern Ontario School of Medicine for up to 8 Mainpro+ credit(s).
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Continuing Education and Professional Development Office at the Northern Ontario School of Medicine. You may claim a maximum of 8 hour(s) (credits are automatically calculated).
AGENDA
Thursday, November 11, 2021 - 12:30 PM – 4:45 PM ET
Pharmacotherapy Primer for the Treatment of Alcohol Use Disorder (AUD) and other Substance Use Disorders (cannabis, stimulant) (2 hour-block)
Presenter: Dr. Valerie Primeau
Session Objectives:
- By the end of this session, the participant will be able to:
- Identify the importance of diagnosing and treating Substance Use Disorders
- Describe the indications, benefits and potential adverse effects of the most common pharmacological agents to treat Substance Use Disorders (with a focus on alcohol, cannabis and stimulants)
- Apply current principles for withdrawal management of common substances
*This session will not cover Opioid Use Disorder
Pharmacotherapy Primer for the Treatment of Opioid Use Disorder (2 hour-block)
Presenters: Dr. Wiplove Lamba and Dr. Mike Franklyn
Session Objectives:
- By the end of this session, the participant will be able to:
- Identify the importance of diagnosing and treating Opioid Use Disorder
- Describe the indications, benefits and potential adverse effects of the most common pharmacological agents to treat Opioid Use Disorder
- Apply current principles for opioid withdrawal management
Friday, November 12, 2021 12:30 PM – 4:45 PM ET
Let’s Discuss! Review of Complex Cases Using a Bio-Psycho-Social Lens for the Treatment of Substance Use Disorders (2 hour-block)
Moderators: Dr. Valerie Primeau, Dr. Wiplove Lamba and Dr. Mike Franklyn
Session Objectives:
- By the end of this session, the participant will be able to:
- Through interactive case discussions, describe the general biopsychosocial approaches to the treatment of concurrent disorders
- Recognize the importance of trauma-informed care
- Appreciate the value in using an integrated approach in the treatment of concurrent disorders
My Experience as an Addiction Physician in Northern Ontario: Adverse Childhood Experiences (ACEs) and the Impact on the Treatment of Mental Health and Addictions (2 hour-block)
Presenter: Dr. Mike Franklyn
Session Objectives:
- Have an enhanced awareness of what constitutes Adverse Childhood Experiences (ACE’s), the profound effect they can have on an individual’s Mental and Physical Health
- Have a greater comfort in recognizing a possible Substance Use Disorder (SUD) and how to facilitate an appropriate, expedited and effective referral for treatment
- Have a greater sense of the ‘treatability’ of various Substance Use Disorders, some of which may not even include a pharmacologically-based treatment
- Recognize the impact that you can have in supporting the patient beginning the “journey of recovery”
PRESENTERS:
Valerie Primeau, MD, FRCPC is a bilingual psychiatrist in North Bay. She has been actively involved in the treatment of concurrent disorders. She is the physician lead for the implementation of medically-supervised withdrawal management at the North Bay Regional Health Centre and the rural implementation of the Centre for Addiction and Mental Health (CAMH) Integrated Care Pathway on alcohol use disorder and depression. She also provides physician leadership at the Rapid Access Addiction Medicine (RAAM) clinic at the Community Counselling Centre of Nipissing. She was a member of the Ontario Health Alcohol Use Disorder Quality Standard Advisory Committee and is helping revise the Withdrawal Management Standards with Addictions and Mental Health Ontario. She sits on the Executive Committee of the Ontario Psychiatric Association and is actively involved in resident education and is currently the North Bay Co-Site Director and Psychotherapy Coordinator for the Northern Ontario School of Medicine (NOSM) Psychiatry Residency Program.
.png)
Dr Mike Franklyn was a family physician practicing in Sudbury for 25 years prior to his retirement in 2018. He served as medical director of the Harm Reduction Home, a CMHA sponsored managed alcohol program for the homeless as well as medical lead of the Sudbury Rapid Access Addiction Medicine Clinic and lead the expansion of RAAM clinics throughout NE Ontario. Dr. Franklyn is an Associate Professor of Family Medicine at the Northern School of Medicine (NOSM) and sat as a member of the CPSO Methadone Specialty Panel and now Quality Assurance and Discipline Committees at the College of Physicians and Surgeons of Ontario. Dr. Franklyn was a contributing author to the Centre for Addictions and Mental Health (CAMH) Buprenorphine Treatment Guidelines and sat on the Executive of PRIMA (Pregnancy Related Issues on the Management of Addictions). He served as a mentor for the OCFP Medical Mentoring in Addiction and Pain and sat on MOHLTC Methadone Treatment and Services Advisory Committee as well as the Health Quality Ontario Opioid Use Disorder Quality Standard Advisory Committee and co-chaired the OH-HQO Alcohol Use Disorder Quality Advisory Committees.
Wiplove Lamba, MD, FRCPC, Dip ABAM, ISAM C, DAPN is an addiction psychiatrist. He has given over 20 workshops at the national level and numerous more at the local and provincial level in helping people build skills in working with those who use substances. He is the regional co-director of Ontario for the Canadian Society of Addiction Medicine and the medical co-lead of ECHO Ontario Addiction Medicine and Psychosocial interventions. He is a member of the motivational interviewing network of trainers. He is excited to work with all of you in teaching and learning together how to best approach people who use substances.
